Advertisement

Topics

Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at ...

22:06 EDT 22 Jun 2017 | BioMedReports - Blog

Results from ongoing study demonstrate increases in hemoglobin and decreases in red blood cell transfusion burden sustained for up to 24 months, with patients still active on treatment

Read more...

Original Article: Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at ...

NEXT ARTICLE

More From BioPortfolio on "Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at ..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...